CytoNiche Expands U.S. FDA Regulatory Filings for 3D RecomTrix Recombinant Collagen Microcarriers

Singapore, Singapore, Aug. 28, 2026 (GLOBE NEWSWIRE) -- CytoNiche Biotech, a pioneer in advanced 3D cell manufacturing technologies, announced a pivotal regulatory milestone in its global expansion strategy. The company’s proprietary 3D RecomTrix recombinant collagen microcarriers (CW01) have formally completed multiple Drug Master File (DMF) and Master File (MF) submissions with the U.S. Food and Drug Administration (FDA). This international achievement follows the successful registration of CW01 as an excipient with the eCentre for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA).

The U.S. regulatory portfolio for 3D RecomTrix CW01 encompasses Type II DMF (Filing No. DMF043937) and Type IV DMF (Filing No. DMF043963) with the FDA Centre for Drug Evaluation and Research (CDER), alongside a Type II Master File (Filing No. MF32742) with the FDA Centre for Biologics Evaluation and Research (CBER). In addition, CW01 holds NMPA CDE Excipient Registration No. F20250000786. By securing comprehensive regulatory backing across both CDER and CBER divisions, CytoNiche reinforces its position as a trusted global supply chain partner, giving biopharma developers the confidence to advance innovative cell therapies toward global commercialisation.

Supporting Regulatory Readiness for Cell and Gene Therapy Manufacturing

As the global cell and gene therapy (CGT) sector matures from clinical development to commercial-scale manufacturing, international regulatory bodies—led by the U.S. FDA—are enforcing rigorous Chemistry, Manufacturing, and Controls (CMC) standards. Ensuring complete raw material traceability, non-animal-derived purity, and stringent risk mitigation against adventitious agents is now paramount for therapeutic developers.

By establishing comprehensive regulatory master files with both the FDA and NMPA, CytoNiche provides global biopharma sponsors with a seamless compliance pathway. Therapeutic developers can directly reference CytoNiche’s confidential technical dossiers to accelerate their own regulatory filings, including Investigational New Drug (IND), New Drug Application (NDA), and Biologics License Application (BLA) submissions.

3D RecomTrix Microcarriers for Scalable 3D Cell Expansion

Tailored specifically for clinical and commercial applications, 3D RecomTrix CW01 microcarriers are synthesised from GMP-grade recombinant collagen, offering a fully defined, animal-free environment for cell expansion:

• High-Surface-Area Architecture: Engineered with an elastic 3D porous structure featuring over 90% porosity and an exceptional specific surface area to maximise yield per unit volume.
• Biomimetic Hydrodynamic Protection: Protects sensitive cells against fluid shear stresses in dynamic bioreactors while integrating proprietary degradation technology for gentle, enzyme-free harvesting.
• Streamlined Automated Workflows: Pre-sterilised via radiation, CW01 microcarriers disperse instantly upon hydration, eliminating pre-treatment steps and enabling rapid integration into automated closed systems.

This achievement builds directly upon CytoNiche’s established track record with its flagship 3D TableTrix Microcarrier Series, which previously completed FDA DMF Type II (Filing No. DMF037798), DMF Type IV (Filing No. DMF035481), and MF Type II (Filing No. MF29721) submissions, alongside two NMPA CDE excipient registrations (Registration Nos. F20200000496 and F20210000003). Matching the proven expansion performance of TableTrix, 3D RecomTrix sets a new benchmark for recombinant, animal-free bioprocessing platforms.

Completing these master files reinforces CytoNiche’s unwavering commitment to setting global quality standards. As regulatory criteria for cell manufacturing continue to heighten, CytoNiche will remain at the forefront—delivering compliant, scalable, and standardised biomanufacturing solutions to partners worldwide.

About CytoNiche

Founded in 2018, CytoNiche Biotech is a pioneering provider of 3D cell mass production systems for therapeutic applications. Built on its proprietary dissolvable microcarrier technology, CytoNiche’s 3D Cell Intelligent Manufacturing system has supported the regulatory approval of China’s first stem cell drug, Amimestrocel Injection. Its flagship 3D FloTrix platform facilitates a seamless transition from antiquated 2D manual cultures to scalable, high-fidelity, closed-system 3D suspension environments and enables cost-effective, large-scale manufacturing of cell and gene therapies. The platform features GMP-compliant dissolvable microcarriers, serum-free media for mesenchymal stromal/stem cells, and a complete suite of automated bioreactors and processing systems and single-use, closed-loop consumables. CytoNiche supports every stage of the cell therapy pipeline—from cell expansion to harvesting, processing, and final fill.

For more information, please visit: en.cytoniche.com

CytoNiche, FloTrix, TableTrix, RecomTrix Architect for Cells and the microcarrier icon are trademarks of CytoNiche Biotech.

Attachment

• CytoNiche Biotech

Winnie Ng
marketing@cytoniche.com
+6589686988

CytoNiche Biotech

CytoNiche Biotech